×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Videos
Maps
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Curis to Release First Quarter 2024 Financial Results and Hold Conference Call on May 7, 2024
KGET.com
LEXINGTON, Mass., April 30, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of...
2 days ago
Curis to Present at Upcoming Healthcare Conferences in April
PR Newswire
PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment...
1 month ago
Curis shares rise as analysts see 'the next Pharmacyclics'
MarketWatch
Shares of Curis rose premarket Friday as analysts see biotech company as potential take-out target.
5 months ago
Curis Announces Initial Combination Study Data from its TakeAim Lymphoma Study
PR Newswire
12, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally...
4 months ago
Curis Provides Fourth Quarter 2023 Business Update
PR Newswire
LEXINGTON, Mass., Feb. 8, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA...
2 months ago
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR Newswire
PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment...
4 weeks ago
Curis Provides Third Quarter 2023 Business Update
PR Newswire
Curis is currently enrolling relapsed or refractory (R/R) AML/MDS patients with FLT3 or spliceosome mutation (U2AF1 or SF3B1) who have received...
6 months ago
Curis Enters into Agreement for Emavusertib / Pembrolizumab Combination Study in Melanoma
PR Newswire
Share this article · Curis is responsible for supply of emavusertib. · Merck is responsible for supply of pembrolizumab and clinical study costs...
4 months ago
Curis Presented Clinical Data from the TakeAim Leukemia Study at the 2023 ASH Conference
PR Newswire
Share this article ... LEXINGTON, Mass., Dec. 11, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the...
4 months ago
Detroit’s East Village Is Being Transformed Into an Art Hub
The New York Times
The founders of a downtown art gallery see the potential for a vibrant community and art hub in the East Village and are putting the pieces...
1 week ago